Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3 Filed transaction by Revance Officer: Cmo & Global Therapeutics Lead. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3

RVNCDelisted Stock  USD 3.65  0.00  0.00%   
About 56% of Revance Therapeutics,'s investor base is looking to short. The analysis of current outlook of investing in Revance Therapeutics, suggests that many traders are alarmed regarding Revance Therapeutics,'s prospects. The current market sentiment, together with Revance Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Revance Therapeutics, stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Revance Officer: Cmo & Global Therapeutics Lead. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Revance insider trading alert for disposition of performance stock units by Hollander David, Officer: Cmo & Global Therapeutics Lead, on 31st of October 2024. This event was filed by Revance with SEC on 2025-02-15. Initial filing of beneficial ownership - SEC Form 3

Revance Therapeutics, Fundamental Analysis

We analyze Revance Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revance Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revance Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Revance Therapeutics, is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Revance Therapeutics, Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Revance Therapeutics, stock to make a market-neutral strategy. Peer analysis of Revance Therapeutics, could also be used in its relative valuation, which is a method of valuing Revance Therapeutics, by comparing valuation metrics with similar companies.

Peers

Revance Therapeutics, Related Equities

IMCRImmunocore Holdings   8.32   
0%
100.0%
BPMCBlueprint Medicines   6.38   
0%
76.0%
AKROAkero Therapeutics   6.16   
0%
74.0%
ETNB89bio   4.98   
0%
59.0%
DAWNDay One   3.96   
0%
47.0%
ACLXArcellx   3.79   
0%
45.0%
NUVLNuvalent   3.31   
0%
39.0%
APLSApellis Pharmaceuticals   3.04   
0%
36.0%
VTYXVentyx Biosciences   2.82   
0%
33.0%
STOKStoke Therapeutics   2.55   
0%
30.0%
TERNTerns Pharmaceuticals   1.96   
0%
23.0%
DMACDiaMedica Therapeutics   0.96   
0%
11.0%
AMLXAmylyx Pharmaceuticals   0.21   
0%
2.0%
MDGLMadrigal Pharmaceuticals   1.13   
13.0%
0%
PLRXPliant Therapeutics   1.48   
17.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Revance Stock

If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated